Without guarantee of delivery or endorsement by the manufacturers, the parallel vaccine market presents offers, at least, suspicious for sale of immunizing against Covid-19. And the proposals even arrive through WhatsApp. It happened with the newspaper Estadão, last week. The German company GB Trading, which sells gloves, masks and alcohol in gel over the internet, presented the vehicle with a proposal for 20 million vials of the Anglo-Swedish vaccine Vaxzevria, from Oxford-AstraZeneca, in the amount of 4 euros a dose (around R $ 26,50). Asked about the security of the purchase, mainly due to the need for a 50% advance payment, the GB Trading representative would have shied away and denied it was a scam.
With prices and delivery schedules of up to 30 days, better conditions than those that the federal government obtained in big negotiations, offers like this seem attractive, but represent the picture of the illegal trade in vaccines.
According to the Pharmaceutical Products Industry Union (Sindusfarma), manufacturers already authorized in Brazil claim that they only sell to Ministry of Health and initiatives such as the Covax Facility, a consortium led by the World Health Organization (WHO), “following international criteria and of collective interest”. “The companies AstraZeneca, Butantan, Janssen and Pfizer are negotiating, supplying and distributing their vaccines against Covid-19 exclusively to federal governments and international public health organizations. Thus, at this time, no company or individual is authorized to negotiate on behalf of these vaccine manufacturers. Covid-19 with no public or private entity, either directly or indirectly ”, says the union's official statement.
Nelson Mussolini, the agency's executive president, guarantees that "serious companies will only supply to governments, even for the reason that governments are assuming the possible adverse effect".
- Anvisa calls on governors to discuss problems with the release of Sputnik V
- What are Pfizer and Moderna thinking about to contain the coronavirus variants?
- Novavax may threaten Pfizer and Moderna in the Covid-19 vaccine market
Despite the manifestations of the manufacturers, large micro entrepreneurs, in addition to mayors and governors, seek immunizers through intercessors. However, sellers in the official market say that no one has been able to import the doses so far. In a clandestine attempt to skip the vaccine line, Minas Gerais businessmen received serum instead of the Pfizer vaccine, according to the Federal Police.
Federal government encourages purchase by private companies
At the beginning of the year, Brazilian businessmen were negotiating the purchase of 33 million vaccines from Oxford-AstraZeneca, for US $ 23,80 each (around R $ 134,10 per dose). The federal government supported the purchase, demanding, in return, the donation of part of the lot to SUS. The deal did not go well, despite the mobilization. Both the manufacturer and the investment fund Blackrock, pointed out by the businessmen as an interlocutor, denied that the doses and the negotiation existed.
The strong lobby to make the purchase of vaccines by the private sector more flexible gives impetus to the market parallel to that of the manufacturers. The topic returned to the focus in a meeting of President Jair Bolsonaro with businessmen, on the last day 7. Justice has given approval to make purchases without the need to donate the entire volume to SUS while priority groups are immunized, as required by law .
The Brazilian Association of Vaccine Clinics (ABCVAC) has an agreement to purchase 5 million doses of Covaxin, a vaccine developed by the Indian Bharat Biotech, through the laboratory's official representative in Brazil, Precis Medicamentos. The forecast is that the doses will cost members from US $ 32,71 (R $ 184,66) to US $ 40,78 (R $ 230,22), but the entity says that the current legislation makes it difficult to negotiate clinics. , as it requires donation of up to the entire volume to SUS. Furthermore, the use of Covaxin has yet to be approved by Anvisa.
Have you watched our new videos on YouTube? Subscribe to our channel!